Cross-Border Impact Ventures is a Toronto impact venture capital firm investing in health technologies that improve outcomes for women, children and adolescents and strengthen health systems. It backs early-growth companies, primarily at Series A and B in North America and Europe, developing medical devices, diagnostics, therapeutics and AI-enabled digital health. The firm supports global commercialization and access in emerging and underserved markets, combining health-impact and gender analysis with investment management. Published holdings include AI fetal-ultrasound software Sonio, cardiac monitoring company Cardiosense, AI proteomics company Oxford Cancer Analytics, oncology software OncoLens and neonatal incubator developer mOm. It launched independently in 2021 after incubation with Grand Challenges Canada.
Founded
—
Type
Venture capital
Funds2
Women’s and Children’s Health Technology Fund II$58M
Second women’s and children’s health technology venture fund at US$58 million first close. It backs early-growth companies, mainly Series A and B, developing medical devices, diagnostics, therapeutics and AI-enabled digital health for conditions affecting women and children specifically, differently or disproportionately. The US$125 million target and expected 2027 final close are future fundraising goals, not raised capital.
Women’s and Children’s Health Technology Fund I$90M
Inaugural early-growth health technology fund investing in medical devices, diagnostics, therapeutics and digital health that improve health outcomes for women, children and adolescents. Final close occurred in November 2023, with the manager publishing its final-close announcement on January 25, 2024. Its 2026 Fund II release gives the exact inaugural amount as US$90.3 million. The 2021 first close is the same vehicle, not a separate eligible fund.
